12:00 AM
 | 
Feb 22, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 2/19 cls
Ardea Biosciences Inc. (NASDAQ:RDEA) Brean Murray Jonathan Aschoff Price target Buy $14.20 -3%
Aschoff raised his target to $23 from $19. He believes Phase IIb data for RDEA594 are unlikely to show renal toxicity issues based in part on data from the Phase IIa trial. Aschoff expects Phase IIb data for the selective URAT1 transporter inhibitor as a monotherapy and also in combination with allopurinol to treat hyperuricemia in patients with gout in March and late April, respectively.
Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) Brean Murray Jonathan Aschoff Price target Sell $30.60 -2%
Jefferies Thomas Wei Price target Buy
Aschoff raised his target to $22 from $17 after Auxilium reported 4Q09 revenue of $48M, beating the Street's...

Read the full 938 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >